NovoCure

NovoCure

NovoCure was founded in 2000 by Yoram Palti, a professor at the Technion – Israel Institute of Technology, who developed the technology behind Tumor Treating Fields (TTFields). William Doyle joined as Executive Chairman early on, providing strategic direction that shepherded the company from its R&D origins in Haifa, Israel, through initial FDA approval for recurrent glioblastoma in 2011, and eventually to a global commercial presence. The company has been publicly traded on NASDAQ since 2015. The firm's strategy centers on the clinical development and commercialization of TTFields, a physics-based modality that deploys alternating electric fields to interrupt mitosis in cancerous cells. The therapy has shown efficacy primarily in glioblastoma, and NovoCure maintains a deep clinical trial pipeline that includes non-small cell lung cancer, pancreatic, ovarian, and brain metastases, often in partnership with major academic research institutions. Geographically, commercial operations span the United States, Europe, Japan, and greater China, with over 3,700 active prescriptions in the U.S. for glioblastoma alone as of its 2023 annual report. Key revenue drivers are the Optune and Optune Lua devices, which are rented on a monthly basis, generating recurring streams that differ from the one-time capital-equipment sales model common in its peer set. The company reported $509.3 million in full-year 2023 net revenues, with a global workforce of roughly 1,400 employees (per NovoCure Q4 2023 Earnings, February 2024). Beyond the Swiss headquarters near Lucerne, major hubs include the U.S. commercial base in Portsmouth, New Hampshire, and the original research center in Haifa. Adjacent efforts include a dedicated philanthropic vehicle, the NovoCure Foundation, and ongoing educational collaborations with the American Brain Tumor Association. May 2024: Announced that the Phase 3 METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer (per NovoCure Press Release, May 2024). Structurally, NovoCure is distinct among oncology companies in that its core IP is rooted in biophysics rather than biochemistry, creating a durable moat in a narrow field with no direct technological competitors. Its long-tenured leadership — Doyle, alongside CEO Asaf Danziger and early scientific founder Yoram Palti — has maintained an unusually stable governance structure for a two-decade-old public biotech. The firm's manufacturing and supply chain, which supports a device rental model, imposes a capital discipline and patient-touch cadence that diverges sharply from the wholesale drug distribution model typical of pharmaceutical peers.